| Literature DB >> 31234852 |
Seung Hyun Lee1, So Ra Oh1, Yeon Jean Cho1, Myoungseok Han1, Jung-Woo Park1, Su Jin Kim1, Jeong Hye Yun1, Sun Yi Choe1, Joong Sub Choi2, Jong Woon Bae3.
Abstract
BACKGROUND: There are various surgical approaches of hysterectomy for benign indications. This study aimed to compare vaginal hysterectomy (VH) and laparoscopic hysterectomy (LH) with respect to their complications and operative outcomes.Entities:
Keywords: Laparoscopic hysterectomy; Meta-analysis; Vaginal hysterectomy
Mesh:
Year: 2019 PMID: 31234852 PMCID: PMC6591934 DOI: 10.1186/s12905-019-0784-4
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Fig. 1PRISMA flow diagram of the study screening and selection process
Fig. 2Risk of bias summary. Green circle (low risk), yellow circle (unclear), red circle (high risk)
Characteristics of included studies
| First author, year | Type of study | Method | Number of patients | Inclusion criteria | Exclusion criteria | Outcomes | Risk of bias according to Cochrane risk of bias tools |
|---|---|---|---|---|---|---|---|
| Agostini, 2006 | RCT | LAVH vs. VH | 48 | Benign uterine diseases, uterine size below pubis, favorable to BSO† | Adnexal mass | Operative data, complications | high |
| Allam, 2015 | RCT | TAH vs.TLH vs. VH | 60 | Benign uterine diseases | Malignancy | Operative data, complications | unclear |
| Candiani, 2009 | RCT | TLH vs. VH | 47 | Benign uterine diseases | Malignancy, estimated uterine volume > 300 mL, POP‡, ovarian pathology, PID§, endometriosis | Operative data, complications | high |
| Darai, 2001 | RCT | LAVH vs. VH | 80 | Estimated uterine size > 280 g, contraindications to VH | Malignancy | Operative data, complications | high |
| Drahonovsky, 2010 | RCT | LAVH vs. TLH vs. VH | 125 | Benign uterine diseases | Impossible VH, prior abdominal surgery, endometriosis, medical disorders | Operative data, complications | high |
| Eggemann, 2018 | RCT | LAVH vs. VH | 192 | Benign uterine diseases, possible VH | Malignancy, POP‡, medical disorders | Operative data, complications | high |
| Garry, 2014 | RCT | Unspecified LH vs. VH | 504 | Benign uterine diseases | Malignancy, POP‡, uterine size > 12 week gestation | Operative data, complications | high |
| Ghezzi, 2010 | RCT | TLH vs. VH | 82 | Benign uterine diseases | Malignancy, POP‡, uterine size > 14 week gestation, large adnexal mass | Operative data, complications | high |
| Hwang, 2002 | RCT | LAVH, vs. TAH vs. VH | 60 | Myoma > 8 cm | other benign gynecological conditions except myoma | Operative data, complications | high |
| Mohammed, 2017 | RCT | LAVH vs. VH | 50 | Benign uterine diseases, age (40–70 years), estimated uterine weight < 280 g | BMI > 30, endometriosis, previous myomectomy, medical disorder | Operative data, complications | unclear |
| Ottosen, 2000 | RCT | LAVH vs. TAH vs. VH | 80 | Benign uterine disease, myoma < 15 cm | Malignancy, uterine size > 16 week gestation, ovarian pathology, dense pelvic adhesion, possible VH | Operative data, complications | high |
| Ribeiro, 2003 | RCT | TAH vs. TLH vs. VH | 40 | Benign uterine diseases | Estimated uterine volume > 400 cm3, medical disorders | Operative data, complications, inflammatory response | high |
| Roy, 2011 | RCT | LAVH vs. TLH vs. VH | 90 | Benign uterine diseases, estimated uterine weight < 400 g | Malignancy, PID§, POP‡ | Operative data, complications | high |
| Soriano, 2001 | RCT | LAVH vs. VH | 77 | Estimated uterine size > 280 g, contraindications to VH | Malignancy | Operative data, complications | high |
| Sesti, 2014 | RCT | LAVH vs. TLH vs. VH | 108 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complications | low |
| Sesti, 2008 | RCT | LAVH vs. TLH vs. VH | 100 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complication | unclear |
| Sesti, 2008 | RCT | LAVH vs. VH | 80 | Symptomatic myoma, age < 55 years, uterine size > 12 week gestation | Malignancy, nulliparity, uterine size > 16 week gestation, previous uterine surgery, | Operative data, complication | unclear |
| Zhu, 2009 | RCT | LAVH vs. VH | 69 | Benign uterine diseases | Malignancy | Operative data, complication | high |
† Bilateral salpingo-oophorectomy
‡ Pelvic organ prolapse
§ Pelvic inflammatory disease
Fig. 3Forest plots of overall (a) and grade I (b) complications
Complications by surgical approach
| First author, year | VH(n) | Overall complications | Grade I complications | Grade II complications | Grade III complications | LH(n) | Overall complications | Grade I complications | Grade II complications | Grade III complications |
|---|---|---|---|---|---|---|---|---|---|---|
| Agostini, 2006 | 24 | 1 | Vault hematoma [ | 0 | 0 | 24 | 3 | Fever [ | 0 | 0 |
| Allam, 2015 | 30 | 9 | Vault hematoma [ | Transfusion [ | Ureteral injury [ | 30 | 1 | 0 | Transfusion [ | 0 |
| Candiani, 2009 | 30 | 6 | Fever [ | DVT† [ | 0 | 30 | 3 | Fever [ | ||
| Darai, 2001 | 40 | 5 | Fever [ | Transfusion [ | 0 | 40 | 9 | Fever [ | Transfusion [ | Cystotomy [ |
| Drahonovsky, 2010 | 40 | 20 | Fever [ vault hematoma [ | Transfusion [ | Cystotomy [ | 85 | 25 | Fever [ vault hematoma [ | Transfusion [ | Cystotomy [ UVF§ [ |
| Eggemann, 2018 | 97 | 3 | Fever [ | Transfusion [ | Cystotomy [ | 95 | 3 | Fever [ | Transfusion [ | Cystotomy [ |
| Garry, 2004 | 168 | 65 | Anesthetic problem [ | Transfusion [ | Cystotomy [ | 336 | 123 | Anesthetic problem [ | Transfusion (39) | Cystotomy [ Pulmonary embolism [ |
| Ghezzi, 2010 | 41 | 4 | Fever [ urinary retention [ | 0 | 0 | 41 | 1 | Urinary retention [ | 0 | 0 |
| Hwang, 2002 | 30 | 5 | Fever [ | Transfusion [ | 0 | 30 | 6 | UTI‡ [ | Transfusion [ | 0 |
| Mohammed, 2017 | 25 | 4 | 0 | Transfusion [ | Cystotomy [ | 25 | 6 | 0 | Transfusion [ | Cystotomy [ |
| Ottosen, 2000 | 40 | 7 | Fever [ | 0 | Reoperation [ | 40 | 4 | Fever [ | 0 | Reoperation [ |
| Ribeiro, 2003 | 20 | 1 | 0 | 0 | Cystotomy [ | 20 | 0 | 0 | 0 | 0 |
| Roy, 2011 | 30 | 8 | Fever [ vaginal bleeding [ | 0 | 0 | 60 | 22 | Fever [ wound infection [ | 0 | 0 |
| Sesti, 2014 | 36 | 1 | Fever [ | 0 | 0 | 72 | 5 | Fever [ | Transfusion [ | 0 |
| Soriano, 2001 | 35 | 1 | 0 | Transfusion [ | 0 | 37 | 1 | 0 | Transfusion [ | 0 |
† Deep vein thrombosis
‡ Urinary tract infection
§ Ureterovaginal fistula
§§ Vesicovaginal fistula
Fig. 4Forest plots of grade II (a) and grade III (b) complications
Fig. 5Forest plot of operating time
Rating of quality of evidence with GRADE system
| Certainty assessment | Number of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | LH | VH | Relative (95% CI) | Absolute (95% CI) | ||
| Overall complications | ||||||||||||
| 17 | randomised trials | serious† | not serious | not serious | not serious | none | 169/887 (19.1%) | 212/1055 (20.1%) | RR 1.11 (0.85 to 1.45) | 22 more per 1000 (from 30 fewer to 90 more) | ⨁⨁⨁◯ MODERATE | none |
| Grade I complications | ||||||||||||
| 17 | randomised trials | serious† | not serious | not serious | not serious | none | 128/887 (14.4%) | 144/1055 (13.6%) | RR 1.20 (0.90 to 1.61) | 27 more per 1000 (from 14 fewer to 83 more) | ⨁⨁⨁◯ MODERATE | none |
| Grade II complications | ||||||||||||
| 17 | randomised trials | serious† | not serious | not serious | not serious | none | 29/887 (3.3%) | 55/1055 (5.2%) | RR 0.78 (0.49 to 1.24) | 11 fewer per 1000 (from 13 more to 27 fewer) | ⨁⨁⨁◯ MODERATE | none |
| Grade III complications | ||||||||||||
| 17 | randomised trials | serious† | not serious | not serious | not serious | none | 12/887 (1.4%) | 14/1055 (1.3%) | RR 1.03 (0.49 to 2.16) | 0 fewer per 1000 (from 7 fewer to 15 more) | ⨁⨁⨁◯ MODERATE | none |
| Urinary tract injuries | ||||||||||||
| 17 | randomised trials | serious† | not serious | not serious | not serious | none | 9/781 (1.2%) | 10/1020 (1.0%) | RR 1.20 (0.50 to 2.85) | 2 more per 1000 (from 5 fewer to 18 more) | ⨁⨁⨁◯ MODERATE | none |
| Operating time | ||||||||||||
| 18 | randomised trials | serious† | not serious | not serious | not serious | none | 922 | 1089 | – | MD 34.01 h lower (45.54 lower to 24.48 lower) | ⨁⨁⨁◯ MODERATE | none |
| Length of hospital stay | ||||||||||||
| 14 | randomised trials | serious‡ | serious§c | not serious | not serious | none | 636 | 809 | – | MD 6.57 h lower (18.65 lower to 5.5 higher) | ⨁⨁◯◯ LOW | none |
| Blood loss | ||||||||||||
| 16 | randomised trials | serious† | serious§ | not serious | not serious | none | 595 | 598 | – | MD 35.91 mL lower (102.26 lower to 30.43 higher) | ⨁⨁◯◯ LOW | none |
| Intraoperative conversion | ||||||||||||
| 7 | randomised trials | serious† | not serious | not serious | not serious | none | 15/771 (1.9%) | 24/939 (2.6%) | RR 0.94 (0.49 to 1.81) | 2 fewer per 1000 (from 13 fewer to 21 more) | ⨁⨁⨁◯ MODERATE | none |
| Recuperation | ||||||||||||
| 4 | randomised trials | serious‡ | serious§ | not serious | not serious | none | 130 | 130 | – | MD 0.66 days higher (0.77 lower to 0.9 higher) | ⨁⨁◯◯ LOW | none |
| Pain on day of surgery (assessed with: Visual analogue scale) | ||||||||||||
| 5 | randomised trials | serious† | not serious | not serious | not serious | none | 325 | 491 | – | MD 0.8 higher (0.08 lower to 1.68 higher) | ⨁⨁⨁◯ MODERATE | none |
| Pain at 24 h after surgery (assessed with: Visual analogue scale) | ||||||||||||
| 4 | randomised trials | serious† | not serious | not serious | not serious | none | 155 | 157 | – | MD 0.53 lower (0.7 lower to 0.35 lower) | ⨁⨁⨁◯ MODERATE | none |
| Pain at 48 h after surgery (assessed with: Visual analogue scale) | ||||||||||||
| 4 | randomised trials | serious† | not serious | not serious | not serious | none | 295 | 461 | – | MD 0.2 lower (0.61 lower to 0.22 higher) | ⨁⨁⨁◯ MODERATE | none |
CI Confidence interval, RR risk ratio, and MD mean difference
† High risk of allocation and blinding
‡ High risk of blinding and incomplete outcome data
§ High heterogeneity